Get the Stockscreener App
7.695
0.09%
-0.005
Overview
News
Price History
Option Chain
Why GRFS Down?
Discussions
Forecast
Stock Split
Dividend History
Grifols Sa Adr stock is traded at $7.695, with a volume of 157.31K.
It is down -0.09% in the last 24 hours and down -15.29% over the past month.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
See More
Previous Close:
$7.69
Open:
$7.59
24h Volume:
157.31K
Relative Volume:
0.26
Market Cap:
$5.23B
Revenue:
$8.51B
Net Income/Loss:
$568.12M
P/E Ratio:
11.42
EPS:
0.6739
Net Cash Flow:
$706.97M
1W Performance:
-4.20%
1M Performance:
-15.29%
6M Performance:
-22.08%
1Y Performance:
-0.86%
1-Day Range:
$7.59
$7.71
1-Week Range:
$7.515
$7.957
52-Week Range:
$6.19
$11.14
Grifols Sa Adr Stock (GRFS) Company Profile
Name
Grifols Sa Adr
Sector
Industry
Phone
-
Address
-
Compare GRFS vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
7.68 | 5.23B | 8.51B | 568.12M | 706.97M | 0.6739 |
LLY
Lilly Eli Co
|
901.72 | 813.11B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.54 | 567.04B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
205.88 | 362.35B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
185.28 | 285.46B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
115.73 | 286.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Resumed | Morgan Stanley | Overweight |
| Mar-12-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-12-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-16-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-18-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-08-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-05-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-19-21 | Downgrade | Barclays | Overweight → Underweight |
| Oct-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-14-21 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-20-21 | Initiated | Deutsche Bank | Hold |
| Mar-23-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-11-21 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-01-20 | Upgrade | Citigroup | Sell → Neutral |
| Jun-09-20 | Downgrade | Citigroup | Neutral → Sell |
| Jun-09-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Mar-25-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-08-19 | Downgrade | Berenberg | Buy → Hold |
| Oct-11-18 | Upgrade | Berenberg | Hold → Buy |
| Jun-01-18 | Initiated | Barclays | Overweight |
| Oct-31-17 | Initiated | Citigroup | Buy |
| Jun-30-17 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-17 | Initiated | BofA/Merrill | Buy |
| Jan-03-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-09-16 | Upgrade | Berenberg | Hold → Buy |
| Jan-04-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-02-15 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-20-15 | Downgrade | Berenberg | Buy → Hold |
| Apr-28-15 | Downgrade | Berenberg | Buy → Hold |
View All
Grifols Sa Adr Stock (GRFS) Latest News
Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS) - Seeking Alpha
Pegasys (Roche, pharmaand) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag - Investing.com India
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag By Investing.com - Investing.com South Africa
Earnings call transcript: Grifols Q4 2025 sees robust growth in IG franchise - Investing.com
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
Contrasting Grifols (NASDAQ:GRFS) & Sigyn Therapeutics (OTCMKTS:SIGY) - Defense World
Airbus SE – Unsponsored ADR (OTCMKTS:EADSY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Grifols S.A. the Most Slept-On Biotech Play Right Now? - AD HOC NEWS
Revenue per share of Grifols, S.A. Sponsored ADR Class A – MUN:G0F - TradingView — Track All Markets
Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS) - Seeking Alpha
European Index Open Up Ahead of Crucial Data Prints -- Market Talk - 富途牛牛
Price to book ratio of Grifols, S.A. Sponsored ADR Class B – BOATS:GRFS - TradingView
Validea's Top Health Care Stocks Based On Martin Zweig11/12/2025 - Nasdaq
Grifols ADR earnings matched, revenue fell short of estimates By Investing.com - Investing.com UK
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols, S.A.American Depositary Shares (Nasdaq:GRFS) Stock Quote - FinancialContent
Validea Joseph Piotroski Strategy Daily Upgrade Report10/10/2025 - Nasdaq
Arm Holdings PLC ADRhedged (BATS:ARMH) Short Interest Down 33.3% in September - Defense World
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
GRDLY Stock Price, Quote and News - Markets.com
Grifols Announces Interim Dividend for 2025 - The Globe and Mail
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - Benzinga
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - The Globe and Mail
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
6 undervalued stocks with low beta - Morningstar
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Spanish court opens investigation into Gotham City's attack on Grifols - Reuters
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Europe Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper - Reuters
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire
Grifols stock falls amid potential Moody's downgrade, new short report - Seeking Alpha
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF - Macau Business
San Gabriel Valley Tribune - FinancialContent
Cramer 'Takes A Pass' On Stock That's Down 31% Over Past 6 Months: 'Don't Want To Go Against Musk' - Sahm
symbol__ Stock Quote Price and Forecast - CNN
BreakingviewsShort attack intensifies Grifols’ health problem - Reuters
Which Trades Are Top Funds Making? - Morningstar Canada
Shares at Spain's Grifols rise on cost-cutting plan - Reuters
Grifols Sa Adr Stock (GRFS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):